Objective: To assess success rates in ability to penetrate (Sexual Encounter Profile question 2 [SEP2]) and maintain erections to completion of intercourse (SEP3) from time of dosing to start of sexual activity in a retrospective analysis of two pivotal trials.
Methods: In two randomized, double-blind studies, men with ED for > 6 months received vardenafil 5 mg, 10 mg, or 20 mg or placebo for 12-26 weeks. Patients were instructed to start sexual activity 1 hour after dosing. In this retrospective pooled analysis, patient diary questions through week 12 were analyzed, providing attempt data was recorded 0-12 hours post-dose. Mean per-patient SEP2 and SEP3 success rates (intent-to-treat population) were calculated by time between dosing and start of sexual activity, from 0-12 hours through week 12. Least-square means and nominal p-values for differences versus placebo were derived by analysis of covariance with terms for baseline, study and treatment.
Results: Most attempts at sexual intercourse occurred 30-90 minutes after dosing: 88%-93% of attempts occurred within 120 minutes. SEP2 success rates in patients choosing to attempt sexual activity in each interval from < or = 15 minutes through the 4-8-hour interval were higher with vardenafil compared with placebo, while SEP3 success rates were greater with vardenafil for patients choosing to initiate sexual activity from < or = 15 min through the 8-12-hour interval. The most commonly reported treatment-emergent adverse events in patients receiving vardenafil included headache (11%-22%), flushing (6%-13%), rhinitis (5%-13%), and dyspepsia (2%-7%).
Conclusion: In this retrospective analysis of two pivotal trials, vardenafil improved success rates compared with placebo in ED patients who attempted intercourse from as early as 15 minutes or less and through 4-8 hours after dosing in ability to penetrate (SEP2) and from as early as 15 minutes or less and through 8-12 hours after dosing in maintenance of erection (SEP3).
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Assessment of the proficiency level of novices in distal intramedullary nail interlocking achieved through training with Digitally Enhanced Hands-on Surgical Training (DEHST).
Eur J Trauma Emerg Surg
January 2025
AO Research Institute Davos, Davos, Switzerland.
Background: Digitally Enhanced Hands-on Surgical Training (DEHST) platform was introduced to overcome the lack of training capabilities for the challenging task of freehand distal interlocking of intramedullary nails. It demonstrates high perceived realism for surgeons, and novices perform significantly better after DEHST training. However, characterization of how performance improves remained unexplored.
View Article and Find Full Text PDFCombating chemoresistance: Current approaches & nanocarrier mediated targeted delivery.
Biochim Biophys Acta Rev Cancer
January 2025
Centre for Medical Biotechnology, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India; Amity Institute of Molecular Medicine and Stem Cell Research, Amity University, Noida, Uttar Pradesh, India. Electronic address:
Chemoresistance, a significant challenge in effective cancer treatment needs clear elucidation of the underlying molecular mechanism for the development of novel therapeutic strategies. Alterations in transporter pumps, oncogenes, tumour suppressor genes, mitochondrial function, DNA repair processes, autophagy, epithelial-mesenchymal transition (EMT), cancer stemness, epigenetic modifications, and exosome secretion lead to chemoresistance. Despite notable advancements in targeted cancer therapies employing both small molecules and macromolecules success rates remain suboptimal due to adverse effects like drug efflux, target mutation, increased mortality of normal cells, defective apoptosis, etc.
View Article and Find Full Text PDFPolysaccharide-based drug delivery targeted approach for colon cancer treatment: A comprehensive review.
Int J Biol Macromol
January 2025
Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. Electronic address:
Colon cancer is a leading cause of cancer-related morbidity and mortality worldwide, necessitating advancements in therapeutic strategies to improve outcomes. Current treatment modalities, including surgery, chemotherapy, and radiation, are limited by systemic toxicity, low drug utilization rates, and off-target effects. Colon-targeted drug delivery systems (CDDS) offer a promising alternative by leveraging the colon's unique physiology, such as near-neutral pH and extended transit time, to achieve localized and controlled drug release.
View Article and Find Full Text PDFPercutaneous biodegradable stent placement for treating benign biliary strictures: a systematic review.
J Vasc Interv Radiol
January 2025
Department of Radiology, Erasmus Medical Center, Rotterdam, The Netherlands. Electronic address:
Purpose: To assess whether safety profile and treatment success of percutaneous biodegradable biliary stent placement are competitive with traditional treatment options for treatment of benign biliary strictures.
Materials And Methods: PubMed and EMBASE were systematically reviewed for articles reporting percutaneous biodegradable stent placement for treating benign biliary strictures. Databases were searched for articles until December 2023, with the earliest included article dating from April 2016.
Experiences of tongue tie when breastfeeding twins: A qualitative study.
Midwifery
January 2025
School of Health, Education, Policing and Sciences, University of Staffordshire, UK.
Problem: Tongue tie is an added complication when breastfeeding, but little is known about the role tongue tie might play when breastfeeding twins.
Background: Twins are much less likely to be breastfed than singleton babies due to added complications regarding pregnancy, birth and ongoing care. Tongue tie can cause breastfeeding barriers including poor latch, inefficient milk transfer and nipple pain.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!